Targeting Pancreatic Stellate Cells in Cancer

Jonas Schnittert; Ruchi Bansal; Jai Prakash

doi:10.1016/j.trecan.2019.01.001

Targeting Pancreatic Stellate Cells in Cancer

Jonas Schnittert, Ruchi Bansal, Jai Prakash^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

110 Citations (Scopus)

743 Downloads (Pure)

Abstract

Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis with a 5-year survival rate of 8%. PSCs constitute more than 50% of the tumor stroma in PDAC, where they induce extensive desmoplasia by secreting abundant extracellular matrix (ECM) proteins. In addition, they establish dynamic crosstalk with cancer cells and other stromal cells, which collectively supports tumor progression via various inter- and intracellular pathways. These cellular interactions and associated pathways may reveal novel therapeutic opportunities against this unmet clinical problem. In this review article, we discuss the role of PSCs in inducing tumor progression, their crosstalk with other cells, and therapeutic strategies to target PSCs.

Original language	English
Pages (from-to)	128-142
Number of pages	15
Journal	Trends in cancer
Volume	5
Issue number	2
DOIs	https://doi.org/10.1016/j.trecan.2019.01.001
Publication status	Published - 1 Feb 2019

Keywords

cancer-associated fibroblasts
desmoplasia
pancreatic cancer
pancreatic ductal adenocarcinoma
tumor stroma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trecan.2019.01.001

Prakash Manuscript Final versionAccepted author version, 1.34 MBLicence: CC BY-NC-ND

Cite this

@article{333a14c1859c4e2b8d325e60ed49ae29,

title = "Targeting Pancreatic Stellate Cells in Cancer",

abstract = "Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis with a 5-year survival rate of 8%. PSCs constitute more than 50% of the tumor stroma in PDAC, where they induce extensive desmoplasia by secreting abundant extracellular matrix (ECM) proteins. In addition, they establish dynamic crosstalk with cancer cells and other stromal cells, which collectively supports tumor progression via various inter- and intracellular pathways. These cellular interactions and associated pathways may reveal novel therapeutic opportunities against this unmet clinical problem. In this review article, we discuss the role of PSCs in inducing tumor progression, their crosstalk with other cells, and therapeutic strategies to target PSCs.",

keywords = "cancer-associated fibroblasts, desmoplasia, pancreatic cancer, pancreatic ductal adenocarcinoma, tumor stroma",

author = "Jonas Schnittert and Ruchi Bansal and Jai Prakash",

year = "2019",

month = feb,

day = "1",

doi = "10.1016/j.trecan.2019.01.001",

language = "English",

volume = "5",

pages = "128--142",

journal = "Trends in cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Targeting Pancreatic Stellate Cells in Cancer

AU - Schnittert, Jonas

AU - Bansal, Ruchi

AU - Prakash, Jai

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis with a 5-year survival rate of 8%. PSCs constitute more than 50% of the tumor stroma in PDAC, where they induce extensive desmoplasia by secreting abundant extracellular matrix (ECM) proteins. In addition, they establish dynamic crosstalk with cancer cells and other stromal cells, which collectively supports tumor progression via various inter- and intracellular pathways. These cellular interactions and associated pathways may reveal novel therapeutic opportunities against this unmet clinical problem. In this review article, we discuss the role of PSCs in inducing tumor progression, their crosstalk with other cells, and therapeutic strategies to target PSCs.

AB - Pancreatic stellate cells (PSCs) are the major contributor to the aggressive, metastatic, and resilient nature of pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis with a 5-year survival rate of 8%. PSCs constitute more than 50% of the tumor stroma in PDAC, where they induce extensive desmoplasia by secreting abundant extracellular matrix (ECM) proteins. In addition, they establish dynamic crosstalk with cancer cells and other stromal cells, which collectively supports tumor progression via various inter- and intracellular pathways. These cellular interactions and associated pathways may reveal novel therapeutic opportunities against this unmet clinical problem. In this review article, we discuss the role of PSCs in inducing tumor progression, their crosstalk with other cells, and therapeutic strategies to target PSCs.

KW - cancer-associated fibroblasts

KW - desmoplasia

KW - pancreatic cancer

KW - pancreatic ductal adenocarcinoma

KW - tumor stroma

UR - http://www.scopus.com/inward/record.url?scp=85060848346&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2019.01.001

DO - 10.1016/j.trecan.2019.01.001

M3 - Review article

AN - SCOPUS:85060848346

SN - 2405-8033

VL - 5

SP - 128

EP - 142

JO - Trends in cancer

JF - Trends in cancer

IS - 2

ER -

Targeting Pancreatic Stellate Cells in Cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this